Abstract
Prostate cancer is one of the most common malignant tumors in the male urinary system as well as the second leading cause of cancer death in men. Prostate specific antigen (PSA) screening is the main method for the early diagnosis of prostate cancer, but has a low specificity for its detection. In recent years, a variety of tumor markers with high sensitivity and specificity have been found. This review focuses on some of the more promising tumor biomarkers such as prostate cancer antigen 3, early prostate cancer antigen, prostate-specific membrane antigen, alpha-methylacyl-CoA racemase, and vascular endothelial growth factor.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antigens, Neoplasm / blood
-
Antigens, Surface / blood
-
Biomarkers, Tumor / blood*
-
Early Detection of Cancer
-
GPI-Linked Proteins / blood
-
Glutamate Carboxypeptidase II / blood
-
Humans
-
Male
-
Neoplasm Proteins / blood
-
Prostate-Specific Antigen / blood
-
Prostatic Neoplasms / diagnosis*
-
Racemases and Epimerases / blood
-
Sensitivity and Specificity
-
Vascular Endothelial Growth Factor A / blood
Substances
-
Antigens, Neoplasm
-
Antigens, Surface
-
Biomarkers, Tumor
-
GPI-Linked Proteins
-
Neoplasm Proteins
-
PSCA protein, human
-
Vascular Endothelial Growth Factor A
-
prostate cancer antigen 3, human
-
FOLH1 protein, human
-
Glutamate Carboxypeptidase II
-
Prostate-Specific Antigen
-
Racemases and Epimerases
-
alpha-methylacyl-CoA racemase